No/DT
Evidence/NN
of/IN
Association/NN
of/IN
Interleukin/NN
1A/NN
(/(
-889/CD
)/)
Genetic/JJ
Polymorphism/NN
with/IN
Alzheimer/NN
’/CD
s/NNS
Disease/NN
in/IN
Koreans/NNS
./.
====================
To/TO
examine/VB
whether/IN
the/DT
IL-1A/NN
(/(
-889/CD
)/)
polymorphism/NN
associates/VBZ
with/IN
a/DT
risk/NN
for/IN
Alzheimer/NN
’/CD
s/NNS
disease/NN
(/(
AD/NN
)/)
and/CC
acts/VBZ
interactively/RB
with/IN
the/DT
apolipoprotein/NN
(/(
APOE/NN
)/)
e/NN
4/CD
in/IN
the/DT
development/NN
of/IN
AD/NN
,/,
we/PRP
performed/VBD
genotype/JJ
analyses/NNS
of/IN
the/DT
IL-1/NN
A/DT
and/CC
the/DT
APOE/NN
of/IN
the/DT
102/CD
Korean/JJ
AD/NN
patients/NNS
and/CC
200/CD
Korean/JJ
non-demented/JJ
controls/VBZ
./.
====================
We/PRP
failed/VBD
to/TO
detect/VB
a/DT
significant/JJ
difference/NN
in/IN
genotypic/JJ
and/CC
allelic/JJ
frequencies/NNS
of/IN
IL-1/NN
A/NN
between/IN
the/DT
AD/NN
group/NN
and/CC
control/NN
group/NN
./.
====================
No/DT
overexpression/NN
of/IN
the/DT
IL-1/NN
A/NN
C/T/NN
genotype/NN
and/CC
IL-1/NN
A/NN
T/NN
allele/NN
was/VBD
found/VBN
when/WRB
we/PRP
analyzed/VBD
the/DT
late-onset/JJ
and/CC
early-onset/JJ
patients/NNS
,/,
separately/RB
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
genetic/JJ
interaction/NN
between/IN
IL-1/NN
A/NN
polymorphism/NN
and/CC
the/DT
APOE/NN
polymorphism/NN
./.
====================
In/IN
conclusion/NN
,/,
the/DT
IL-1/NN
A/NN
polymorphism/NN
did/VBD
not/RB
contribute/VB
to/TO
the/DT
development/NN
of/IN
AD/NN
independently/RB
or/CC
interactively/RB
with/IN
the/DT
APOE/NN
s4/NN
allele/NN
in/IN
Koreans/NNS
./.
====================
lnterleukin-1/NN
(/(
IL-1/NN
)/)
,/,
a/DT
potent/JJ
acute/JJ
phase/NN
proinflammatory/JJ
cytokine/NN
,/,
is/VBZ
known/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
development/NN
of/IN
Alzheimer/NN
’/CD
s/NNS
disease/NN
(/(
AD/NN
)/)
./.
====================
It/PRP
was/VBD
reported/VBN
to/TO
regulate/VB
amyloid/NN
beta/NN
protein/NN
(/(
Af/JJ
)/)
production/NN
and/CC
increase/VBP
the/DT
phosphorylation/NN
of/IN
tau/NN
protein/NN
(/(
Sheng/NN
etal./FW
,/,
1996/CD
,/,
2000/CD
)/)
./.
====================
Its/PRP$
level/NN
was/VBD
elevated/JJ
in/IN
cerebral/JJ
cortex/NN
and/CC
cerebrospinal/JJ
fluid/NN
of/IN
AD/NN
patients/NNS
,/,
and/CC
activated/VBD
IL-1/NN
immunoreactive/JJ
microglia/NNS
were/VBD
also/RB
proliferated/VBD
significantly/RB
in/IN
the/DT
cerebral/JJ
cortex/NN
of/IN
AD/NN
patients/NNS
(/(
Griffin/NN
et/FW
al./FW
,/,
1989/CD
;/:
Cacabelos/NN
etal./FW
,/,
1991/CD
)/)
./.
====================
In/IN
2000/CD
,/,
Grimaldi/NNP
and/CC
his/NN
colleagues/NNS
reported/VBD
that/IN
the/DT
genetic/JJ
polymorphism/NN
in/IN
the/DT
promoter/NN
region/NN
of/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
was/VBD
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AD/NN
./.
====================
In/IN
their/PRP$
population/NN
,/,
the/DT
IL-1/NN
AT/IN
allele/NN
conferred/VBD
the/DT
risk/NN
of/IN
AD/NN
in/IN
dose-dependent/JJ
manner/NN
./.
====================
The/DT
odds/NNS
ratios/NNS
for/IN
AD/NN
in/IN
the/DT
IL-1/NN
A/NN
T-heterozygous/JJ
subjects/NNS
were/VBD
1.84/CD
and/CC
those/DT
of/IN
IL-1/NN
A/NN
T-homozygous/JJ
subjects/NNS
were/VBD
6.33/CD
./.
====================
The/DT
association/NN
of/IN
AD/NN
with/IN
IL-1/NN
A/NN
polymorphism/NN
was/VBD
also/RB
replicated/VBD
in/IN
several/JJ
other/JJ
populations/NNS
(/(
Du/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Nicoll/NN
et/FW
al./FW
,/,
2000/CD
;/:
Rebeck/NN
,/,
2000/CD
;/:
Combarros/NN
et/FW
al./FW
,/,
2002/CD
;/:
Hedley/RB
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Moreover/RB
,/,
this/DT
polymorphism/NN
might/MD
be/VB
functional/JJ
./.
====================
The/DT
IL-1ATT/NN
genotype/NN
significantly/RB
increased/VBD
the/DT
transcriptional/JJ
activity/NN
of/IN
the/DT
IL-1/NN
alpha/NN
gene/NN
with/IN
respect/NN
to/TO
the/DT
CC/NN
genotype/NN
(/(
Dominici/NNS
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
However/RB
,/,
there/EX
was/VBD
substantial/JJ
ethnic/JJ
difference/NN
in/IN
the/DT
allelic/JJ
frequency/NN
of/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
and/CC
IL-1A/NN
T-conferred/JJ
AD/NN
risk/NN
./.
====================
While/IN
the/DT
frequency/NN
of/IN
the/DT
IL-1A/NN
T/NN
was/VBD
17.8/CD
%/NN
-/:
33/CD
%/NN
in/IN
Caucasians/JJ
(/(
Du/NNP
etal./FW
,/,
2000/CD
;/:
Grimaldi/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Minster/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Nicoll/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Rebeck/NNP
,/,
2000/CD
;/:
Kolsch/RB
etal./FW
,/,
2001/CD
;/:
Combarros/NNP
etal./FW
,/,
2002/CD
;/:
Fidani/NNP
etal./FW
,/,
2002/CD
;/:
Green/NNP
etal./FW
,/,
2002/CD
;/:
Hedley/RB
etal./FW
,/,
2002/CD
;/:
Pirskanen/NNP
et/FW
al./FW
,/,
2002/CD
)/)
,/,
it/PRP
was/VBD
less/RBR
than/IN
11.3/CD
%/NN
in/IN
East/JJ
Asians/JJ
(/(
Ki/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Kuo/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Tsai/NNP
et/FW
al./FW
,/,
2003/CD
)/)
and/CC
the/DT
IL-1/NN
A/DT
T-AD/NN
association/NN
was/VBD
not/RB
significant/JJ
in/IN
Asians/JJ
(/(
Ki/NNP
etal./FW
,/,
2001/CD
;/:
Kuo/NNP
etal./FW
,/,
2003/CD
;/:
Tsai/NNP
etal./FW
,/,
2003/CD
)/)
./.
====================
Therefore/RB
we/PRP
investigated/VBD
the/DT
association/NN
of/IN
AD/NN
with/IN
the/DT
IL-1A/NN
(/(
-889/CD
)/)
polymorphism/NN
and/CC
examined/VBN
its/PRP$
interaction/NN
with/IN
APOE/NN
polymorphism/NN
in/IN
the/DT
development/NN
of/IN
AD/NN
in/IN
Koreans/NNS
./.
====================
The/DT
AD/NN
patients/NNS
were/VBD
selected/VBN
from/IN
the/DT
patients/NNS
who/WP
had/VBD
visited/VBN
the/DT
dementia/NN
clinic/NN
at/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
and/CC
from/IN
the/DT
community-dwelling/VBG
====================
elderly/JJ
individuals/NNS
in/IN
three/CD
districts/NNS
of/IN
Seoul/JJ
(/(
Kwanak-gu/NNP
,/,
Seocho-gu/NN
,/,
Nowon-gu/NNP
)/)
./.
====================
All/DT
the/DT
non-demented/JJ
normal/JJ
control/JJ
subjects/NNS
were/VBD
community-dwelling/VBG
elderly/JJ
individuals/NNS
randomly/RB
selected/VBN
from/IN
those/DT
three/CD
districts/NNS
./.
====================
We/PRP
administered/VBD
the/DT
Korean/JJ
version/NN
of/IN
the/DT
CERAD/NN
assessment/NN
packet/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2002/CD
)/)
and/CC
Modified/JJ
Hachinski/NNP
Ischemic/JJ
Score/NNP
(/(
MHIS/NN
)/)
(/(
Rosen/NNP
et/FW
al./FW
,/,
1980/CD
)/)
to/TO
all/DT
the/DT
subjects/NNS
./.
====================
Following/VBG
this/DT
evaluation/NN
,/,
a/DT
diagnosis/NN
for/IN
each/DT
subject/JJ
was/VBD
made/VBN
at/IN
a/DT
consensus/NN
meeting/VBG
;/:
diagnoses/NNS
for/IN
dementia/NN
were/VBD
made/VBN
according/VBG
to/TO
DSM-IV/NN
criteria/NNS
(/(
APA/NN
,/,
1994/CD
)/)
and/CC
diagnoses/NNS
for/IN
probable/JJ
AD/NN
according/VBG
to/TO
NINCDS-ADRDA/NN
criteria/NNS
(/(
McKhann/NNP
et/FW
al./FW
,/,
1984/CD
)/)
./.
====================
The/DT
subjects/NNS
who/WP
were/VBD
diagnosed/VBN
as/IN
cognitively/RB
normal/JJ
and/CC
got/NN
less/RBR
than/IN
3/CD
of/IN
MHIS/NN
were/VBD
included/VBN
in/IN
the/DT
normal/JJ
control/JJ
group/NN
./.
====================
Age-at-onset/NN
was/VBD
defined/VBN
as/IN
the/DT
age/NN
at/IN
which/WDT
the/DT
patient/NN
or/CC
his/DT
family/NN
first/JJ
noticed/VBN
the/DT
symptoms/NNS
required/VBN
for/IN
the/DT
diagnosis/NN
./.
====================
The/DT
cut-off/JJ
between/IN
late-onset/JJ
AD/NN
and/CC
early-onset/JJ
AD/NN
was/VBD
65/CD
years/NNS
of/IN
age/NN
./.
====================
The/DT
control/JJ
subjects/NNS
were/VBD
also/RB
divided/VBN
into/IN
the/DT
young/JJ
controls/NNS
aged/JJ
64/CD
years/NNS
or/CC
less/RBR
and/CC
the/DT
old/JJ
controls/NNS
aged/JJ
65/CD
years/NNS
or/CC
over/IN
./.
====================
The/DT
subjects/NNS
with/IN
cerebrovascular/JJ
disorders/NNS
,/,
neurologic/JJ
disorders/NNS
,/,
and/CC
psychiatric/JJ
disorders/NNS
including/VBG
depression/NN
were/VBD
excluded/VBN
from/IN
the/DT
patient/NN
group/NN
as/IN
well/RB
as/IN
the/DT
control/NN
group/NN
./.
====================
The/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
,/,
Korea/NN
,/,
approved/JJ
the/DT
study/NN
protocol/NN
and/CC
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
participants/NNS
or/CC
their/PRP$
guardians/NNS
./.
====================
Genomic/JJ
DNA/NN
for/IN
genotyping/VBG
was/VBD
extracted/VBN
from/IN
peripheral/JJ
venous/JJ
blood/NN
./.
====================
IL-1A/NN
(/(
-889/CD
)/)
polymorphism/NN
was/VBD
determined/VBN
using/VBG
a/DT
dynamic/JJ
allele/NN
specific/JJ
hybridization/NN
method/NN
(/(
DASH/NN
)/)
(/(
Howell/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
The/DT
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
primers/NNS
(/(
forward/IN
,/,
5/CD
-1/CD
I/NN
I/NN
I/NN
IACATAT/NN
GAGCCTTCAAT-3/NN
'/``
;/:
biotinylated/VBN
reverse/JJ
,/,
5-TTAATAATAG/NN
TAACCAGGCAAC-3/NN
'/``
)/)
and/CC
the/DT
two/CD
fluorescent/JJ
labeled/VBN
probes/NNS
(/(
5/CD
’/NN
-AGGCAACATCAT/JJ
TGAAG-3/NN
’/NNP
and/CC
5-AGGC/NN
A/DT
ACACCATTGAAG-3/NN
'/``
)/)
,/,
complementary/JJ
to/TO
the/DT
both/DT
allelic/JJ
sequences/NNS
of/IN
the/DT
IL-1/NN
A/DT
(/(
-889/CD
)/)
polymorphism/NN
,/,
were/VBD
added/VBN
to/TO
a/DT
96-well/JJ
microtiter/RB
plate/VBP
,/,
and/CC
PCR/NN
was/VBD
then/RB
performed/VBN
./.
====================
After/IN
PCR/NN
,/,
the/DT
plate/NN
was/VBD
placed/VBN
in/IN
a/DT
DASH/NN
====================
instrument/JJ
(/(
Hybaid/NN
ltd./FW
)/)
and/CC
heated/JJ
from/IN
35°C/NN
to/TO
85°C/NN
at/IN
a/DT
rate/NN
of/IN
0.3°C/sec/JJ
./.
====================
Probe-duplex/NN
denaturation/NN
was/VBD
determined/VBN
by/IN
the/DT
decrease/NN
in/IN
fluorescence/NN
./.
====================
The/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
genotypes/NNS
were/VBD
determined/VBN
from/IN
the/DT
fluorescence/NN
curves/NNS
as/IN
previously/RB
described/VBN
(/(
Howell/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
APOE/NN
genotyping/VBG
was/VBD
performed/VBN
using/VBG
a/DT
slight/JJ
modification/NN
of/IN
the/DT
method/NN
reported/VBD
by/IN
Wenham/JJ
et/FW
al/JJ
./.
====================
(/(
1991/CD
)/)
./.
====================
The/DT
differences/NNS
in/IN
both/DT
allele/NN
and/CC
genotype/NN
frequency/NN
between/IN
the/DT
AD/NN
patients/NNS
and/CC
the/DT
control/NN
subjects/NNS
were/VBD
compared/VBN
using/VBG
either/CC
a/DT
Fisher/JJ
's/POS
exact/JJ
test/NN
or/CC
Pearson/NN
Chi/NN
square/VBP
test/NN
when/WRB
appropriate/JJ
./.
====================
Logistic/JJ
regression/NN
analyses/NNS
controlling/VBG
for/IN
age/NN
(/(
age/NN
at/IN
onset/NN
for/IN
AD/NN
)/)
,/,
gender/RB
and/CC
APOE/NN
genotype/NN
were/VBD
performed/VBN
to/TO
calculate/JJ
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
associated/VBN
with/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
polymorphism/NN
on/IN
the/DT
risk/NN
for/IN
AD/NN
./.
====================
And/CC
the/DT
age/NN
at/IN
onset/NN
between/IN
groups/NNS
was/VBD
compared/VBN
using/VBG
Student/JJ
T/NN
test/NN
./.
====================
SPSS/NN
version/NN
10.0/CD
for/IN
Windows/VBZ
was/VBD
used/VBN
for/IN
these/DT
statistical/JJ
analyses/NNS
./.
====================
A/DT
total/JJ
of/IN
102/CD
sporadic/JJ
AD/NN
patients/NNS
and/CC
200/CD
controls/NNS
were/VBD
enrolled/VBN
in/IN
this/DT
study/NN
./.
====================
Among/IN
the/DT
102/CD
AD/NN
patients/NNS
,/,
34/CD
subjects/NNS
were/VBD
early-onset/RB
AD/NN
patients/NNS
(/(
age/NN
at/IN
onset/NN
=/JJ
58.8+3.7/CD
years/NNS
,/,
age/NN
-/:
62.8+3.6/CD
years/NNS
,/,
range/NN
=/JJ
54-71/CD
years/NNS
,/,
58.3/CD
%/NN
female/JJ
)/)
and/CC
68/CD
subjects/NNS
were/VBD
late-onset/RB
AD/NN
patients/NNS
(/(
age/NN
at/IN
onset/NN
=/JJ
75.3±35.9/CD
years/NNS
,/,
age/NN
=/JJ
78.3±5.8/CD
years/NNS
,/,
range/NN
-/:
67-97/CD
years/NNS
,/,
67.6/CD
%/NN
female/JJ
)/)
./.
====================
The/DT
200/CD
control/NN
subjects/NNS
were/VBD
also/RB
stratified/VBD
by/IN
age/NN
into/IN
38/CD
young/JJ
controls/NNS
(/(
age/NN
=/JJ
60.8±3.0/CD
years/NNS
,/,
range/NN
=/JJ
53-64/CD
years/NNS
,/,
89.5/CD
%/NN
female/JJ
)/)
and/CC
162/CD
old/JJ
controls/NNS
(/(
age/NN
=/JJ
72.6±5.7/CD
years/NNS
,/,
range/NN
=/JJ
65-88/CD
years/NNS
,/,
72.8/CD
%/NN
female/JJ
)/)
./.
====================
There/EX
were/VBD
no/DT
significant/JJ
differences/NNS
in/IN
the/DT
allelic/JJ
and/CC
genotypic/JJ
frequencies/NNS
of/IN
the/DT
IL-1A/NN
polymorphism/NN
between/IN
the/DT
AD/NN
patients/NNS
and/CC
control/NN
subjects/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
distributions/NNS
of/IN
the/DT
IL-1A/NN
(/(
-889/CD
)/)
and/CC
APOE/NN
genotypes/NNS
were/VBD
in/IN
Hardy-Weinberg/JJ
equilibrium/NN
in/IN
both/CC
the/DT
AD/NN
patients/NNS
and/CC
controls/VBZ
./.
====================
The/DT
frequency/NN
of/IN
the/DT
T/NN
====================
allele/DT
was/VBD
7.5/CD
%/NN
in/IN
our/PRP$
normal/JJ
elderly/JJ
controls/NNS
,/,
and/CC
the/DT
IL-1A/NN
T-homozygous/JJ
subject/JJ
was/VBD
not/RB
observed/VBN
in/IN
both/DT
the/DT
patient/NN
group/NN
and/CC
control/JJ
group/NN
,/,
which/WDT
was/VBD
quite/RB
consistent/JJ
with/IN
the/DT
previously/RB
reported/VBN
results/VBZ
in/IN
Koreans/NNS
(/(
Ki/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
As/IN
expected/VBN
,/,
the/DT
APOE/NN
e4/NN
was/VBD
more/RBR
prevalent/JJ
in/IN
the/DT
AD/NN
patients/NNS
than/IN
in/IN
the/DT
controls/NNS
(/(
p/NN
</JJR
0.C0001/CD
)/)
./.
====================
However/RB
,/,
the/DT
IL-1A/NN
T/NN
allele/NN
was/VBD
not/RB
overrepresented/VBN
in/IN
the/DT
AD/NN
group/NN
compared/VBD
with/IN
the/DT
control/NN
group/NN
(/(
P/NN
>/JJR
0.1/CD
)/)
./.
====================
The/DT
IL-1/NN
A/NN
T-AD/NN
association/NN
was/VBD
not/RB
significant/JJ
either/CC
after/IN
stratifying/JJ
the/DT
subjects/NNS
by/IN
the/DT
type/NN
of/IN
AD/NN
(/(
Table/JJ
1/CD
)/)
or/CC
the/DT
presence/NN
of/IN
APOE/NN
e/NN
4/CD
allele/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
age-/NN
and/CC
gender-adjusted/VBD
odds/NNS
ratio/NN
for/IN
AD/NN
conferred/VBD
to/TO
the/DT
IL-1/NN
A/NN
T/NN
was/VBD
0.61/CD
(/(
95/CD
%/NN
C.l/NN
./.
====================
The/DT
age-at-onset/NN
was/VBD
not/RB
influenced/VBN
by/IN
the/DT
IL-1/NN
A/NN
polymorphism/NN
./.
====================
The/DT
mean/JJ
age-at-onset/NN
of/IN
the/DT
AD/NN
patients/NNS
with/IN
the/DT
IL-1/NN
A/NN
C/C/NN
genotype/NN
(/(
69.9±9.4/CD
years/NNS
)/)
was/VBD
not/RB
different/JJ
from/IN
that/DT
of/IN
the/DT
AD/NN
patients/NNS
with/IN
IL-1/NN
A/NN
C/T/NN
genotype/NN
(/(
69.0±9.4/CD
years/NNS
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
did/VBD
not/RB
find/VB
a/DT
significant/JJ
association/NN
between/IN
the/DT
IL-1/NN
A/DT
(/(
-889/CD
)/)
polymorphism/NN
and/CC
AD/NN
risk/NN
in/IN
Koreans/NNS
,/,
which/WDT
is/VBZ
consistent/JJ
with/IN
the/DT
three/CD
previous/JJ
studies/NNS
on/IN
Asians/NNS
(/(
Ki/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Kuo/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Tsai/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
However/RB
,/,
the/DT
absence/NN
of/IN
association/NN
between/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
polymorphism/NN
and/CC
AD/NN
in/IN
the/DT
present/JJ
study/NN
is/VBZ
not/RB
merely/RB
attributed/VBN
to/TO
the/DT
ethnic/JJ
difference/NN
./.
====================
Five/CD
out/IN
of/IN
the/DT
11/CD
previous/JJ
studies/NNS
on/IN
Caucasians/NNS
could/MD
not/RB
find/VB
any/DT
significant/JJ
association/NN
either/CC
(/(
Minster/NN
et/FW
al./FW
,/,
2000/CD
;/:
Kolsch/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Fidani/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Green/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Pirskanen/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Therefore/RB
,/,
another/DT
factors/NNS
including/VBG
lack/NN
of/IN
power/JJR
and/CC
linkage/NN
disequilibrium/NN
of/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
polymorphism/NN
with/IN
other/JJ
nearby/JJ
responsible/JJ
gene/NN
on/IN
chromosome/NN
2/CD
could/MD
====================
be/VB
the/DT
sources/NNS
of/IN
the/DT
conflicting/VBG
results/NNS
./.
====================
The/DT
frequency/NN
of/IN
the/DT
IL-1/NN
A/DT
T/NN
allele/NN
in/IN
our/PRP$
controls/NNS
,/,
7.5/CD
%/NN
,/,
was/VBD
much/RB
lower/RBR
than/IN
those/DT
of/IN
Caucasians/JJ
which/WDT
were/VBD
reported/VBN
to/TO
be/VB
17.8/CD
%/NN
-/:
33/CD
%/NN
(/(
Du/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Grimaldi/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Minster/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Nicoll/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Rebeck/NNP
,/,
2000/CD
;/:
Kolsch/RB
et/FW
al./FW
,/,
2001/CD
;/:
Combarros/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Fidani/NNP
eta/FW
!/RB
./.
,/,
2002/CD
;/:
Green/NNP
etal./FW
,/,
2002/CD
;/:
Hedley/RB
et/FW
al./FW
,/,
2002/CD
;/:
Pirskanen/NNP
et/FW
al./FW
,/,
2002/CD
)/)
,/,
but/CC
it/PRP
was/VBD
similar/JJ
to/TO
thoseof/DT
East/JJ
Asians/JJ
(/(
7.1/CD
%/NN
-11.3/CD
%/NN
;/:
Ki/NNP
etal./FW
,/,
2001/CD
;/:
Kuo/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Tsai/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Therefore/RB
,/,
in/IN
East/JJ
Asians/NNS
,/,
much/RB
larger/JJR
sample/JJ
size/NN
may/MD
be/VB
required/VBN
for/IN
verifying/VBG
the/DT
same/JJ
odds/NNS
ratio/NN
for/IN
AD/NN
conferred/VBD
to/TO
the/DT
IL-1/NN
A/NN
T/NN
compared/VBN
with/IN
Caucasians/NNS
./.
====================
Because/IN
of/IN
this/DT
lowT/JJ
allele/NN
frequency/NN
as/IN
well/RB
as/IN
the/DT
insufficient/JJ
sample/JJ
size/NN
,/,
the/DT
power/JJ
of/IN
the/DT
present/JJ
study/NN
was/VBD
65/CD
%/NN
if/IN
we/PRP
considered/VBD
that/IN
the/DT
odds/NNS
of/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
allele/NN
for/IN
AD/NN
were/VBD
2/CD
./.
====================
Moreover/RB
,/,
there/EX
was/VBD
no/DT
IL-1/NN
A/NN
T/NN
homozygous/JJ
subject/JJ
in/IN
our/PRP$
sample/NN
./.
====================
Among/IN
the/DT
six/CD
previous/JJ
positive/JJ
studies/NNS
(/(
Du/NNP
etal./FW
,/,
2000/CD
;/:
Grimaldi/NNP
etal./FW
,/,
2000/CD
;/:
Nicoll/NNP
etal./FW
,/,
2000/CD
;/:
Rebeck/NNP
,/,
2000/CD
;/:
Combarros/NN
et/FW
al./FW
,/,
2002/CD
;/:
Hedley/RB
et/FW
al./FW
,/,
2002/CD
)/)
,/,
three/CD
studies/NNS
found/VBD
that/IN
only/RB
T/T/JJ
genotype/NN
was/VBD
significantly/RB
associated/VBN
with/IN
AD/NN
risk/NN
(/(
Nicoll/NN
et/FW
al./FW
,/,
2000/CD
;/:
Rebeck/NNP
,/,
2000/CD
;/:
Hedley/RB
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Therefore/RB
the/DT
association/NN
between/IN
AD/NN
and/CC
IL-1/NN
A/NN
T/T/JJ
in/IN
Korean/JJ
was/VBD
not/RB
examined/VBN
in/IN
the/DT
present/JJ
study/NN
,/,
and/CC
waits/VBZ
for/IN
further/JJ
investigation/NN
in/IN
an/DT
extended/JJ
sample/NN
./.
====================
In/IN
other/JJ
three/CD
studies/NNS
that/IN
the/DT
dose-dependent/JJ
AD/NN
risk/NN
conferred/VBD
to/TO
IL-1/NN
AT/IN
allele/NN
was/VBD
confirmed/VBN
(/(
Du/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Grimaldi/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Combarros/NN
etal./FW
,/,
2002/CD
)/)
,/,
the/DT
AD/NN
risks/NNS
conferred/VBD
to/TO
IL-1/NN
A/DT
(/(
-889/CD
)/)
C/T/NN
genotype/NN
were/VBD
less/RBR
than/IN
2/CD
(/(
1.39/CD
-/:
1.84/CD
)/)
./.
====================
This/DT
modest/VBP
contribution/NN
of/IN
IL-1/NN
A/NN
T/NN
allele/NN
may/MD
====================
further/RB
complicate/VB
the/DT
power/NN
of/IN
present/JJ
study/NN
./.
====================
Age-at-onset/NN
was/VBD
also/RB
suggested/VBD
to/TO
be/VB
a/DT
confounding/VBG
factor/NN
to/TO
influence/VB
on/IN
the/DT
association/NN
of/IN
IL-1A/NN
(/(
-889/CD
)/)
polymorphism/NN
with/IN
AD/NN
./.
====================
While/IN
the/DT
association/NN
of/IN
AD/NN
with/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
polymorphism/NN
was/VBD
significant/JJ
only/RB
in/IN
early-onset/JJ
cases/NNS
in/IN
Glimaldi/NN
et/FW
al/JJ
./.
====================
(/(
2000/CD
)/)
and/CC
Rebeck/NN
(/(
2000/CD
)/)
,/,
it/PRP
was/VBD
significant/JJ
only/RB
in/IN
====================
late-onset/RB
cases/NNS
in/IN
Hedley/JJ
et/FW
al/JJ
./.
====================
(/(
2002/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
limited/JJ
association/NN
of/IN
IL-1A/NN
(/(
-889/CD
)/)
polymorphism/NN
with/IN
AD/NN
according/VBG
to/TO
age/NN
at/IN
onset/NN
is/VBZ
still/RB
controversial/JJ
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
association/NN
of/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
was/VBD
not/RB
found/VBN
either/CC
in/IN
the/DT
early/JJ
onset/NN
AD/NN
patients/NNS
or/CC
in/IN
the/DT
late-onset/JJ
AD/NN
patients/NNS
./.
====================
Combarros/NN
etal/JJ
./.
====================
(/(
2002/CD
)/)
reported/VBD
that/IN
in/IN
the/DT
presence/NN
of/IN
the/DT
APOE/NN
e4/NN
allele/NN
the/DT
relative/JJ
risk/NN
of/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
allele/NN
carriers/NNS
was/VBD
approximately/RB
double/JJ
the/DT
risk/NN
of/IN
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
allele/NN
non-carriers/NNS
./.
====================
However/RB
,/,
in/IN
the/DT
present/JJ
study/NN
,/,
the/DT
association/NN
of/IN
AD/NN
with/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
was/VBD
not/RB
significant/JJ
regardless/RB
of/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
the/DT
APOE/NN
e4/NN
allele/NN
./.
====================
Thus/RB
the/DT
absence/NN
of/IN
the/DT
AD-/NN
IL-1/NN
A/NN
(/(
-889/CD
)/)
T/NN
association/NN
in/IN
our/PRP$
sample/NN
was/VBD
not/RB
a/DT
biased/JJ
result/NN
confounded/VBD
by/IN
the/DT
APOE/NN
polymorphism/NN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
failed/VBD
to/TO
find/VB
any/DT
evidence/NN
supporting/VBG
an/DT
association/NN
between/IN
the/DT
IL-1/NN
A/NN
(/(
-889/CD
)/)
genetic/JJ
polymorphism/NN
and/CC
AD/NN
in/IN
Koreans/NNS
./.
====================
We/PRP
also/RB
did/VBD
not/RB
find/VB
any/DT
significant/JJ
association/NN
after/IN
the/DT
stratification/NN
according/VBG
to/TO
age/NN
at/IN
onset/NN
or/CC
APOE/NN
genotype/NN
./.
====================
